BiotechTube

SHR-3167 + SHR-3167 Placebo

Phase 1UNKNOWN
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

T2DM

Conditions

T2DM

Trial Timeline

Jun 9, 2023 → Apr 28, 2024

NCT ID
NCT05996380

About SHR-3167 + SHR-3167 Placebo

SHR-3167 + SHR-3167 Placebo is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for T2DM. The current trial status is unknown. This product is registered under clinical trial identifier NCT05996380. Target conditions include T2DM.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT05996380Phase 1UNKNOWN

Competing Products

20 competing products in T2DM

See all competitors
ProductCompanyStageHype Score
MKP10241 + PlaceboMankind PharmaPhase 2
52
Metformin + Alogliptin + empagliflozinCelltrionPhase 3
77
CT-L03 Group 1 + CT-L03 Group 2 + Placebo + Empagliflozin + MetforminCelltrionPhase 3
77
L03RD1 + L03RD2 + CT-L03CelltrionPhase 1
33
DulaglutideEli LillyPhase 1
33
AZD4076 + PlaceboAstraZenecaPhase 1
33
Xigduo (Dapagliflozin and Metformin hydrochloride extended-release) tablets + Dapagliflozin tablets and Metformin HCl extended-release tabletsAstraZenecaApproved
85
Dapagliflozin + Metformin XR + GlucophageAstraZenecaPhase 1
33
AZD8601+Placebo (SAD) + AZD8601+Placebo + Placebo+PlaceboAstraZenecaPhase 1
33
Saxagliptin 5 mg + Metformin XR 500 mg + Mertformin XR 2 x 500 mg + Komboglyze XR 5/500 mg + Komboglyze XR 5/1000 mgAstraZenecaPhase 1
33
Comparator: sitagliptin phosphate + Comparator: placebo (unspecified)MerckPhase 1
33
ErtugliflozinMerckPhase 1
33
Comparator: sitagliptin phosphate + Comparator: pioglitazone + Comparator: placebo to pioglitazone + Comparator: placebo to sitagliptinMerckPhase 1
33
Sitagliptin phosphate + Comparator: Sulfonylurea + MetforminMerckApproved
85
sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day + comparator: placebo to match sitagliptin 100 mg q.d./metformin ≥ 1500 mg/dayMerckPhase 3
77
Vildagliptin (LAF237) + Placebo + Insulin + MetforminNovartisApproved
85
LIK066 + PlaceboNovartisPhase 1/2
41
Vildagliptin + Metformin + sulfonylurea (SU) + Basal InsulinNovartisPhase 3
77
Maridebart cafraglutide + PlaceboAmgenPhase 3
76
Maridebart Cafraglutide + PlaceboAmgenPhase 2
51

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85